Market Trends of Global Monoclonal Antibody Therapeutics Industry
This section covers the major market trends shaping the Monoclonal Antibody Therapeutics Market according to our research experts:
Autoimmune Diseases are Expected to Hold the Significant Market Share in the Monoclonal Antibody Therapeutics Market
Autoimmune diseases are anticipated to witness growth in the market due to the global prevalence of various diseases such as rheumatoid arthritis, psoriatic arthritis, Crohn's disease, uveitis, and juvenile idiopathic arthritis. For instance, as per the October 2021 CDC update, by 2040, an estimated 78 million (26%) United States adults aged 18 years or older are projected to have doctor-diagnosed arthritis.
Also, the availability of products such as Humira, a fully human monoclonal antibody approved by the US FDA for the treatment of rheumatoid arthritis fueling the market. In August 2021, FDA approved the use of a new version of a HUMIRA biosimilar known as HADLIMA to treat certain autoimmune disorders. The increased research based on the advancement of monoclonal antibodies in autoimmune disease is an uplifting growth factor in the market. For instance, as per the article published in February 2022 in Technology Networks, using an anti-CD6 monoclonal antibody to block the CD6-ALCAM pathway in models of systemic lupus erythematosus (SLE) and lupus nephritis (LN) resulted in prolonged survival. Furthermore, as per the August 2022 update from Penn Medicine, an experimental drug called litifilimab (known as BIIB059) is likely to be a powerful long-term treatment for cutaneous lupus erythematosus (CLE), a form of lupus that occurs in the skin and can severely impact the quality of life. This kind of clinical study is fuelling the growth of the segment and propelling the global monoclonal antibody therapeutics market revenue in the forecast period.
Hence, due to the rise in autoimmune disease, and the increase in product launches in monoclonal antibody therapeutics for autoimmune disease, the autoimmune segment in the monoclonal antibody market is likely to witness growth over the forecast period.
North America is Anticipated to Witness a Growth in the Monoclonal Antibody Therapeutics Market Over the Forecast Period
North America is expected to hold a significant share in the overall monoclonal antibody therapeutics market throughout the forecast period owing to the factors such as a rise in autoimmune diseases, increased healthcare expenditure, huge investments by the key players, and continuous growth in R&D activities with the rise in application of these therapeutics in the treatment of various disorders such as (PCOS) polycystic ovary syndrome, breast cancers in the United States. For instance, as per Breast Cancer.Org, in 2022, an estimated 287,850 new cases of invasive breast cancer are expected to be diagnosed in women in the United States., along with 51,400 new cases of non-invasive (in situ) breast cancer.
Furthermore, the presence of competitors and their product launches relating to the area of monoclonal antibodies are a major fuelling factor for the market growth. For instance, as per the August 2022 update, AstraZeneca and Daiichi Sankyo's Enhertu (trastuzumab deruxtecan) was approved in the United States for the treatment of adult patients with unresectable or metastatic HER2-low (IHC 1+ or IHC 2+/ISH-) breast cancer who have received prior chemotherapy in the metastatic setting or developed disease recurrence during or within six months of completing adjuvant chemotherapy. Moreover, collaborations relating to the research and development of monoclonal antibodies in different cancer treatment is likely to boost the market growth. For instance, as per the March 2022 update, Sanofi and Blackstone agreed to a strategic, risk-sharing collaboration under which funds managed by Blackstone Life Sciences (BXLS) that is likely to contribute up to EUR 300 million to accelerate the pivotal global studies and the clinical development program for the subcutaneous formulation and delivery of the anti-CD38 antibody Sarclisa, to treat patients with multiple myeloma (MM). If successful, BXLS is anticipated to be eligible to receive royalties on future subcutaneous sales. The pivotal study for the subcutaneous formulation is expected to begin in the second half of 2022.
Hence, due to the rise in chronic diseases and autoimmune diseases, and the increase in product launches in monoclonal antibody therapeutics, strategic partnerships involving the expansion of monoclonal antibody development, North America is anticipated to witness growth in the monoclonal antibody market over the forecast period.
